Edition:
India

GTX Inc (GTXI.OQ)

GTXI.OQ on NASDAQ Stock Exchange Capital Market

17.30USD
22 Jun 2018
Change (% chg)

$-1.19 (-6.44%)
Prev Close
$18.49
Open
$18.59
Day's High
$18.90
Day's Low
$17.17
Volume
471,458
Avg. Vol
37,064
52-wk High
$23.36
52-wk Low
$4.24

Select another date:

Wed, May 30 2018

Deutsche Boerse beefs up forex business with $100 million buy

BERLIN Deutsche Boerse AG is beefing up its foreign exchange business with a $100 million deal to buy GTX's Electronic Communication Network (ECN) business from GAIN Capital Holdings Inc.

Deutsche Boerse beefs up forex business with $100 mln buy

BERLIN, May 30 Deutsche Boerse AG is beefing up its foreign exchange business with a $100 million deal to buy GTX's Electronic Communication Network (ECN) business from GAIN Capital Holdings Inc.

BRIEF-GTX Announces Early Completion Of Patient Enrollment In The Astrid Trial

* GTX ANNOUNCES EARLY COMPLETION OF PATIENT ENROLLMENT IN THE ASTRID TRIAL, A PHASE 2 CLINICAL TRIAL OF ENOBOSARM IN STRESS URINARY INCONTINENCE

BRIEF-GTX Inc Q4 Loss Per Share $0.43

* GTX PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-GTx Announced New Data Demonstrating Enobosarm's Potential To Treat Stress Urinary Incontinence At SUFU 2018

* GTX ANNOUNCED NEW DATA DEMONSTRATING ENOBOSARM’S POTENTIAL TO TREAT STRESS URINARY INCONTINENCE AT SUFU 2018

BRIEF-GTx Trial Results In Stress Urinary Incontinence Accepted For Podium Presentation At SUFU

* GTX PHASE 2 ENOBOSARM CLINICAL TRIAL RESULTS IN STRESS URINARY INCONTINENCE ACCEPTED FOR PODIUM PRESENTATION AT SUFU Source text for Eikon: Further company coverage:

Select another date: